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ABSTRACT 
Introduction: Hypertension is emerging as a pandemic in the society. Though a lot of 
potent antihypertensive drugs are available today but none of them is free from untoward 
effects. Especially the elderly population poorly tolerates these drugs.  
Objective: This study was conducted to clinically evaluate the efficacy of an Ayurvedic 
formulation in the management of essential hypertension in elderly patients. 
Materials and Methods: 45 patients of either sex of stage-I essential hypertension in the 
age group of 60-90 years were registered for the present study. Patients with stage-II 
hypertension, and secondary hypertension were excluded from study. Registered patients 
were randomly divided into two groups. In group-I patients were managed with Tagar 
Churna, Gokshur Churna and Triphla Churna. Group-II patients were managed with a 
standard calcium channel blocker drug Amlodipine. The duration of trial was 30 days.  
Observations: After one month of therapy statistically highly significant reduction in 
systolic B.P., diastolic B.P. mean arterial B.P. and pulse pressure was observed in both 
groups. Pulse rate was statistically significantly reduced in group-I patients. Biochemical 
studies revealed a beneficial effect on serum lipid profile in group-I patients whereas in 
group-II patients it remained unchanged.  
Conclusion: It is evident from results of the study that combination of Tagar and Gokshura 
along with Triphala Churna possess potent antihypertensive activity. Combination of trial 
herbs appear to be safe for elderly hypertensive patients when given in mentioned doses 
and duration as no untoward effect of therapy was observed during the study period.  
KEYWORDS: Hypertension, Herbal drugs, Tagar, Gokshur, Triphala.  
INTRODUCTION 
India is labeled as global capital of 
hypertension due to the presence of maximum 
number of hypertensive patients in the country. 
Hypertension affects approximately one billion 
individuals worldwide. It is a multifactorial 
disease where age is also becoming an important 
predisposing factor. Hypertension is a major risk 
factor for the development of coronary artery 
disease, stroke, congestive heart failure and renal 
disorders1. Recent data from Framingham Heart 
Study suggest that individuals who are 
normotensive at the age of 55 have a ninety 
percent risk for developing hypertension2. In 
clinical trials, antihypertensive therapy has been 
associated with reduction in stroke incidence 
averaging 35-40 percent; myocardial infarction, 
20-25 percent; and heart failure, more than 50 
percent3. Recent clinical trials have demonstrated 
that effective blood pressure control can be 
achieved in most patients who are hypertensive. 
However, majority will require two or more 
antihypertensive drugs4. Currently, numbers of 
effective antihypertensive drugs are available. 
However, they are not free from side effects. 
Especially the elderly population poorly tolerates 
these drugs due to above said reasons. Beta 
blockers often cause fatigue, cold extremities, 
bradycardia and heart-failure. Similarly, 
angiotensin converting enzyme inhibitors may 
cause cough and rash5 etc. Ideally, an 
antihypertensive drug should achieve optimum 
blood pressure control and improve patient’s well 
being. Any treatment administered should be 
directed not only to control blood pressure, but 
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also prevent target organ damage, thereby 
preserving cardiac and renal functions which may 
also increase patient’s life span6-7. Therefore 
based on these parameters we have tried to 
develop a safe anti hypertensive therapy with the 
help of an Ayurvedic herbal formulation. 
Many herbs are described in Ayurveda 
which have diuretic, cardio protective and anti 
stress activities. Of these, Gokshur (Tribulus 
terrestris L.) and Tagar (Valeriana wallichi DC.) 
have been found to show potent antihypertensive 
activity in animals8,10,11. Gokshur is documented to 
have, antihypertensive10, ACE inhibiter11, anti 
dyslipidemic12 and diuretic13 properties. 
Objectives of the Research work 
To clinically evaluate the efficacy of 
Gokshur (Tribulus terrestris L.) and Tagar 
(Valeriana wallichi DC.) with Triphla Churna 
(powder) in the management of Essential 
Hypertension in Elderly patients. 
Place of Study: The study was conducted as a 
part of post graduate thesis research work in P.G. 
department of Kayachikitsa of Rajiv Gandhi Govt. 
Post Graduate Ayurvedic College & Hospital 
Paprola, Himachal Pradesh in the year 2010. 
Materials and Methods 
The present study was open, single blind 
and double group in nature. The study was 
conducted on 45 patients of essential 
hypertension selected from OPD and IPD of 
associated hospital of Rajiv Gandhi Govt. Post 
Graduate Ayurvedic College, Paprola (H.P.). 
Patients of stage-I essential hypertension (JNC-7) 
in the age group of 60-90 years were registered 
irrespective of caste, sex, race and religion after 
obtaining their written informed consent. 5 
patients did not turn up for follow up. They were 
considered dropped out from the study. 
Remaining 40 patients completed the trial.  
Criteria of Diagnosis  
Diagnosis was mainly based on readings of 
sphygmomanometer. With the help of 
sphygmomanometer, 3 consecutive readings of 
blood pressure in 3 different positions (sitting, 
standing and supine) on both arms were taken. 
Their mean value was calculated for each arm 
separately and the higher reading was utilized for 
diagnosing and categorizing the patients 
according to VII Joint National Committee on 
Detection, Education and Treatment of High Blood 
Pressure. To determine systolic and diastolic 
blood pressure the Kortokoff sound I and V were 
used. 
Inclusion Criteria 
1. Patients in age-group between 60-90 years. 
2. Patients suffering from stage-I hypertension 
(Systolic Blood pressure 140–159 mmHg and 
diastolic blood pressure 90-99 mmHg) and 
isolated systolic hypertension (Systolic Blood 
pressure ≥140 mmHg and diastolic blood 
pressure <90 mmHg)  
Exclusion Criteria  
1. Stage II Hypertension i.e. Systolic B.P.>160 
mmHg. and/ or Diastolic B.P.> 100 mmHg. 
2. Secondary hypertension including endocrinal 
disorders, renal disease and hypertension 
associated with pregnancy. 
Method of study: After registration patients were 
given the medicine and were followed up initially 
after 3 days and then after 10 days till completion 
of trial i.e., 30 days. The selected patients were 
divided into two groups.  
Group-I (Trial group) Total 25 patients were 
registered in this group, out of them 5 patients 
discontinued the treatment and only 20 patients 
completed the trial. In this group hypertensive 
patients were treated with following drugs. 
1. Tagar Churna (powder):  1gm BD with water. 
2. Gokshur Churna (powder): 6gm BD with 
water. 
3. Triphla Churna (powder): was given in the 
dose of 6gm at bed time with Luke warm water 
for 7 days in the beginning of trial along with 
other trial drugs. 
Trial drugs were prepared in state 
Ayurvedic pharmacy Paprola, H.P. which is G.M.P. 
certified. 
Gokshur (Tribulus terrestris L.) fruits were 
grinded to prepare fine powder. Tagar (Valeriana 
wallichi DC.) roots were also grinded to prepare 
fine powder. Triphla Churna was prepared by 
combining the powder of fruits of Haritaki 
(Terminalia chebula Retz.), Vibhitak (Terminalia 
bellirica Gaertn.) and Amalaki (Emblica officinalis 
Gaertn.) in equal quantity.  
Group-II (Standard group): Total 20 patients 
were registered in this group and all the patients 
completed the trial. In this group patients were 
managed with a standard calcium channel blocker 
drug Amlodipine. It was given once a day schedule 
in a dose of 5 mg in the morning hours. 
Investigations 
Following investigations were carried out 
to rule out any other concomitant disease, 
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secondary hypertension and to see any untoward 
effect of the trial drugs both before and after the 
therapy. 
Blood - Hb%, TLC, DLC, ESR, Blood Urea, S. 
Creatinine, FBS, Lipid profile (LDL, VLDL, HDL, S. 
Triglycerides, S. Cholestrol), S.G.O.T., S.G.P.T. 
Urine- Routine and Microscopic, ECG, X-ray Chest, 
USG/IVP/X-ray KUB - if felt necessary. 
Duration: The duration of trial was 30 days. 
Criteria for Assessment 
Assessment of the effects of therapy was 
done on the basis of various objective and 
subjective parameters. However the change in 
systolic, diastolic and mean blood pressure was 
the main criteria. Signs and symptoms were 
graded according to severity.  
 
Objective parameters: By noting down the 
alteration in blood pressure, pulse pressure, mean 
arterial pressure and pulse rate  
Table: Gradation of subjective parameters 
Subjective parameters Gradation Score 
Shira shoola 
(Headache) 
No Headache 0 
Mild - able to do daily work  1 
Moderate - hampers routine work 2 
Severe - unable to any work 3 
Bhrama 
(Giddiness) 
No Giddiness 0 
Mild - able to do daily work 1 
Moderate - hampers routine work 2 
Severe - unable to any work 3 
Hridadrava 
(Palpitation) 
No palpitation 0 
Occasional palpitation 1 
Palpitation which hampers routine work 2 
Continuous palpitation  3 
Shwasa 
(Breathlessness) 
No dyspnoea on exertion 0 
Mild dyspnoea on exertion 1 
Moderate dyspnoea on little exertion 2 
Severe dyspnoea with/without little exertion  3 
Data Collection and Statistical Analysis: Data generated from clinical study was collected and analyzed 
statistically. The improvement in the status of patient was assessed on the grades of various variables 
compared between pre-trial and post-trial values in terms of percentage (based on mathematical mean 
and its difference) and the student ‘t’ tests was applied wherever it was felt necessary by using degree of 
freedom value. The results were interpreted at the level of p<0.001 as highly significant, p<0.01 as 
moderately significant, p<0.05 as significant and p>0.05 as insignificant. 
Results 
Table 1: Showing statistical analysis of Objective parameters in both groups 
Variable in 
mm Hg 
Group-I Group – II 
Mean Score % 
Change 
SD SE + t P Mean Score % 
Change 
SD SE + t P 
BT AT BT AT 
Systolic BP 148.40 132.00 11.05 05.83 01.30 12.50 <0.001 150.00 125.50 16.30 07.81 01.74 14.02 <0.001 
Diastolic BP 87.50 84.50 03.42 03.74 00.83 09.40 <0.001 91.40 82.70 09.51 03.62 00.80 11.30 <0.001 
Mean 
Arterial 
Pressure 
111.46 100.30 10.01 03.51 0.78 14.21 <0.001 110.80 97.03 12.42 02.71 0.60 22.72 <0.001 
Pulse 
Pressure 
60.90 47.50 22.00 07.55 01.83 05.80 <0.001 58.60 42.80 26.96 06.80 01.50 10.45 <0.001 
Pulse Rate 85.10 79.40 06.69 02.92 00.65 08.72 <0.001 79.90 82.90 03.75 02.38 00.53 05.63 <0.001 
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Table 2: Showing statistical analysis of Subjective parameters in both groups 
Subjective 
parameters 
Group-I Group – II 
Mean Score % 
Change 
SD SE + t P Mean Score % 
Change 
SD SE + t P 
BT AT BT AT 
Headache 0.80 00.15 81.25 00.67 0.14 04.31 <0.001 02.00 00.88 56.23 00.35 00.13 09.00 <0.001 
Giddiness 02.00 01.00 50.00 00.87 00.29 03.46 <0.01 02.00 00.67 66.27 00.82 00.33 04.00 <0.01 
Palpitation 00.90 00.45 50.00 00.60 00.13 03.31 <0.001 0.98 0.56 43.18 0.49 0.07 5.68 <0.001 
Breathless
ness 
02.00 00.89 55.56 00.60 00.20 05.51 <0.001 01.45 00.81 37.54 00.52 00.15 03.46 <0.01 
Table 3: Showing statistical analysis of objective/lab parameters in both groups 
Variable  Group-I  Group – II 
Mean Score % 
Change 
SD SE + t P Mean Score % 
Change 
SD SE + t P 
BT AT BT AT 
Hb% 11.43 11.58 01.30 00.48 00.10 0.09 >0.05 11.14 11.34 01.75 00.39 00.10 00.08 >0.05 
TLC 8075 7595 05.94 893 199.7 02.43 <0.05 7856.3 7837 00.24 379.8 84.90 10.73 <0.001 
ESR 10.25 8.95 12.68 04.28 00.95 01.35 >0.05 12.06 07.94 34.16 03.72 00.83 04.43 <0.001 
Polymorphs 55.19 59.39 07.60 09.41 01.69 02.48 <0.05 56.79 59.84 05.37 06.08 01.39 02.19 <0.05 
Lymphocytes 38.48 34.09 11.40 08.10 01.61 02.71 <0.05 36.63 34.15 06.87 05.95 01.37 01.85 >0.05 
Monocytes 02.87 02.81 02.09 00.77 00.17 00.46 >0.05 02.95 03.10 05.36 00.96 00.22 00.72 >0.05 
Eosinophils 02.69 01.38 48.69 01.09 00.25 05.18 <0.001 01.86 01.10 40.80 00.77 00.20 03.80 <0.01 
F.B.S.  83.81 82.53 01.53 01.37 00.30 03.74 <0.01 82.00 79.40 03.17 10.11 02.26 01.88 >0.05 
B. Urea  26.65 25.90 02.81 03.99 00.89 00.84 >0.05 26.73 23.38 12.53 03.23 00.72 04.14 <0.01 
S.Creatinine 00.73 00.69 05.47 00.17 00.03 00.70 >0.05 00.60 00.55 08.30 00.04 00.08 05.28 <0.01 
SGOT 27.35 17.71 35.24 6.22 1.66 5.79 <0.01 29.00 33.85 16.72 3.43 0.91 5.28 <0.01 
SGPT 27.36 19.71 27.96 3.81 1.01 7.49 <0.01 27.86 30.57 09.72 4.71 1.25 2.15 >0.05 
S. Cholesterol 237.20 223.35 05.87 14.24 03.87 3.66 <0.01 226.91 216.0 04.80 21.91 04.90 03.80 >0.05 
S. Triglyceride 187.17 173.42 07.37 18.80 05.07 2.71 <0.05 164.02 158.9 03.09 15.61 03.49 05.00 >0.05 
HDL 037.41 39.20 04.78 02.60 00.68 2.56 <0.05  37.13  37.46 0.88 1.53 0.23 1.35 >0.05 
LDL 159.99 153.35 04.15 15.28 04.09 2.07 <0.05 155.67 150.2 03.51 15.08 03.37 07.70 >0.05 
VLDL 39.08 37.88 03.07 08.14 02.17 0.73 >0.05  37.80  37.47 0.87 1.43 0.21 1.57 >0.05 
Table 4: Showing comparison of effect of therapies between two groups 
Group-I V/s Group-II Comparison Mean Difference t P 
Systolic Blood Pressure 5.25 3.76 <0.01 
Diastolic Blood Pressure 6.09 5.08 <0.001 
Mean Arterial Pressure 02.41 02.90 <0.01 
Pulse Pressure 04.96 03.17 <0.01 
Pulse Rate 02.74 07.37 <0.001 
Headache 25.02 02.90 <0.01 
Giddiness 16.27 01.95 >0.05 
Palpitation 05.56 03.20 <0.01 
Breathlessness 40.96 05.41 <0.01 
Among the total 45 registered patients, 40 
patients i.e. 20 patients in group-I and 20 patients 
in group-II completed the trial successfully. In 
both groups the effect of therapy showed 
statistically highly significant reduction in systolic 
blood pressure, diastolic blood pressure, pulse 
pressure and mean blood pressure (P<0.001). 
Ayurvedic herbal formulations and Amlodipine 
reduced (P<0.001) systolic, diastolic, pulse 
pressure and mean blood pressure in a similar 
manner. Inter group comparison showed 
significant difference between two therapies in 
reduction of systolic, diastolic, pulse pressure and 
mean blood pressure (P<0.01) (Table 4). 
Amlodipine reduced systolic, diastolic, pulse 
pressure and mean blood pressure to the greater 
extent than Ayurvedic formulation. Pulse rate was 
increased significantly (P<0.001) by Amlodipine, 
whereas trial drugs caused statistically highly 
significant reduction in pulse rate (P<0.001). 
However pulse rate remained within normal 
range in both groups both before and after the 
therapy (Table 1). In both groups the effects of 
therapy on the subjective parameters was highly 
significant and the intergroup comparison showed 
that therapy in group-I had statistically significant 
advantage over therapy used in group-II on 
headache, palpitation, and breathlessness (Table 
No. 4). Most of the base line hematological and 
biochemical parameters remained within normal 
 Int. J. Ayur. Pharma Research, 2015;3(1):72-77  ISSN: 2322 - 0910 
 Available online at: http://ijapr.in Page 76 
limits before and after the therapy in both the 
groups. Serum cholesterol and other components 
of lipid profile were significantly (p<0.01) reduced 
whereas serum HDL was significantly increased 
after the treatment in trial group-I (Table No. 3). 
In group-II no effect on serum lipid profile was 
observed after the therapy. 
DISCUSSION 
 Increasing rate of hypertension is the 
major risk factors for cardiovascular mortality. 
Hypertension can be controlled in almost all the 
patients with the currently available drugs. 
However, none of the currently available 
antihypertensive drugs are free from side effects. 
Recent clinical trials have demonstrated that 
majority of hypertensive patients require two or 
more antihypertensive drugs for optimum blood 
pressure control. Due to multiple drug therapy the 
annoying side effects are further augmented, 
leading to decreased compliance in a symptomatic 
patient. The present trial is an attempt to develop 
an ideal herbal antihypertensive formulation 
which is safe for long term use. 
 In this study the antihypertensive 
therapies in both the groups showed statistically 
highly significant effect in reduction of systolic 
blood pressure, diastolic blood pressure, mean 
arterial pressure and pulse pressure. In terms of 
subjective parameters, trial herbal drugs showed 
statistically highly significant effect and it also 
showed statistically significant advantage over 
control group drug in all subjective symptoms 
except in giddiness in which the intergroup 
comparison showed statistically insignificant 
difference (Table No. 4). The trial drug also 
showed significant advantage over control group 
drug in improvement of lipid profile (Table No. 3). 
During the course of treatment all the patients 
reported a feeling of well being and no untoward 
effects were observed. 
 Hypertension accelerates the development 
of atherosclerosis, especially when combined with 
other risk factors like dyslipidemia. After the 
treatment the drug formulation significantly 
(P<0.001) lowered serum cholesterol level (Table 
No. 3). It was further observed that patients 
treated with herbal drugs formulation developed 
a sense of well being, increased physical and 
mental fitness after the course of therapy. No side 
effect was reported during or after the therapy. 
The possible action of drug formulation could be a 
result of reduced peripheral resistance, diuretic, 
decreased sympathetic tone and A.C.E. inhibiter 
activities8,10,11,13. One of the trial drug Gokshur is 
documented to have beneficial effect on 
dyslipidemia12. Further studies to understand the 
detailed mechanism of action of trial drugs are 
warranted. 
CONCLUSIONS 
On the basis of results obtained, it is clear 
that trial herbal drugs possess statistically 
significant antihypertensive activity though it is 
lesser than Amlodipin with no observed side 
effects. Thus it can be concluded that Tagar 
Churna and Gokshur Churna along with Triphla 
Churna could be used effectively in the 
management of essential hypertension. 
Furthermore, it may prove more useful in 
managing the hypertensive patients having 
concomitant dyslipidemia as the trial drug also 
possess significant hypolipidemic activities. More 
studies are required for thorough assessment of 
antihypertensive potential of trial drug. 
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